Bullish case
$38 to $42
More likely if oncology and obesity assets advance, Seagen integration improves growth, COVID product declines stabilize, debt falls, the dividend remains covered, and investors value PFE near a low-teens earnings multiple.
Pfizer Inc. research snapshot
PFE AI Stock Analysis
PFE AI stock analysis currently reads Pfizer Inc. as a broad biopharma franchise trying to rebuild durable growth after the COVID-19 revenue reset. At the July 8, 2026 data cutoff, PFE traded near $24.07 with an implied market capitalization of about $137.95 billion. The positive case depends on oncology, obesity, vaccines, cost discipline, balance sheet repair, and acquired assets converting into earnings growth. The risk case centers on patent losses, COVID product decline, high debt from the Seagen deal, dividend coverage pressure, and uncertain pipeline timing. This page is informational research, not investment advice.
Current price
$24.07
Market cap
$137.95 billion
AI score
58 / 100
Rating
Recovering large-cap pharma with high yield and pipeline risk
Trend status
Weak technical trend below major moving averages
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Pfizer has long public filings, detailed annual and quarterly releases, liquid market data, broad analyst coverage, and multiple independent financial data providers.
- bias Check
- The main AI bias risk is anchoring on Pfizer as a legacy blue-chip dividend stock while under-weighting how much COVID sales, patent losses, debt, R&D intensity, and acquired oncology assets can change normalized earnings.
- ai Confidence
- High for reported revenue, net income, share count, cash, debt, dividend, and market cap math. Medium for forward valuation because obesity, oncology, patent expiry timing, pricing pressure, and acquisition execution remain uncertain.
- investment Certainty
- Medium-low. The information base is strong, but investment certainty is lower because Pfizer must prove that the post-COVID portfolio can grow while supporting a large dividend and reducing leverage.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Pfizer sells prescription medicines, vaccines, oncology therapies, and specialty products across global regulated markets, with revenue now less dependent on pandemic products than in 2021 and 2022. | High |
| Moat | The moat comes from patents, clinical data, regulatory approvals, manufacturing scale, payer access, physician trust, and global commercial reach, but it weakens when exclusivity expires. | Medium-high |
| Management | Chairman and CEO Albert Bourla is steering a rebuild around oncology, obesity, cost savings, capital discipline, and business development after the COVID demand cliff. | Medium |
| Financial trend | FY2025 revenue declined 1.7% to $62.579 billion, net income was $7.787 billion, and Q1 2026 revenue grew 5% to $14.5 billion while management reaffirmed full-year guidance. | High |
| Valuation | At $24.07, PFE traded near 18.4x TTM GAAP EPS, 14.5x TTM free cash flow per share, 1.5x book value, 2.2x sales, and a 7.1% dividend yield. | Medium-high |
| Technical trend | The stock was below its 50-day and 200-day moving averages, with neutral RSI readings and support near the low $23 area. | Medium |
| Risk level | The biggest risks are patent expirations, weak COVID product demand, regulatory pricing pressure, trial failure, integration risk, high debt, and dividend sustainability. | Medium-high |
| AI confidence | High for descriptive research and arithmetic checks. Lower for exact stock outcomes because PFE can reprice quickly around trial data, FDA decisions, patent news, guidance, rates, and dividend expectations. | High data confidence |
| Investment certainty | Medium-low certainty. Pfizer has scale and cash flow, but a buy decision depends on whether new products and cost actions can offset patent and COVID product pressure. | Medium-low |
PFE AI stock forecast
PFE AI Stock Forecast Scenarios
The PFE AI stock forecast uses scenario math around the $24.07 quote and the midpoint of 2026 adjusted EPS guidance near $2.90 as a normalized earnings base. The audited three-year framework produced a bearish area near $18.5, a base area near $30.8, and a bullish area near $40.3 before dividends.
Base case
$29 to $32
More likely if adjusted EPS grows at a low-single-digit pace, patent pressure is manageable, cost savings hold, and the market applies about a 10x multiple to normalized earnings.
Bearish case
$17 to $20
More likely if pipeline assets disappoint, Eliquis or other patent losses pressure revenue faster than launches scale, COVID sales keep falling, leverage limits flexibility, or the dividend is questioned.
PFE AI technical analysis
PFE AI Technical Analysis
PFE AI technical analysis was weak as of the July 8, 2026 cutoff. PFE traded near $24.07, while third-party snapshots placed the 50-day moving average around $24.08 to $25.30 and the 200-day moving average around $25.25 to $25.90. RSI readings were neutral rather than washed out, so price still needs confirmation above moving averages before the trend improves.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $24.07 | StockAnalysis closing quote for July 7, 2026 used for market cap and valuation math at the July 8, 2026 cutoff. |
| Near support | $23.67 to $24.00 | AltIndex listed support near $23.67, while Investing.com daily pivots clustered around $23.96 to $24.01. |
| Near resistance | $25.25 to $28.08 | The first resistance area is the 200-day moving average zone, with six-month resistance listed near $28.08. |
| 50-day moving average | About $24.08 to $25.30 | Investing.com and AltIndex snapshots differed by provider, but both showed the stock struggling around or below the 50-day trend area. |
| 200-day moving average | About $25.25 to $25.90 | PFE remained below the longer moving average zone, which keeps the larger technical trend cautious. |
| Momentum | RSI about 39 to 51 | AltIndex and Investing.com both placed RSI in neutral territory, not extreme oversold or overbought territory. |
| Volume | Event-sensitive large-cap liquidity | Volume confirmation matters around earnings, trial updates, FDA decisions, dividend news, and guidance changes. |
| Volatility | Moderate but catalyst-driven | Large-cap pharma volatility can expand when patent, pipeline, litigation, pricing, or capital allocation news changes the earnings view. |
| Invalidation | Close below $23.67, then failure near $25.25 | A break below support weakens mean-reversion setups. A failed move back above the 200-day area keeps the trend-following setup unconfirmed. |
PFE AI trading strategy
PFE AI Trading Strategy Framework
The PFE AI trading strategy is a rules-based research framework for a large-cap pharma stock with high dividend yield, weak moving-average trend, and material pipeline and patent-cycle catalysts. It is not personal advice and should be paired with live quotes, filings, event calendars, and position sizing rules.
Trend-following setup
Watch for PFE to reclaim the $25.25 to $25.90 moving-average zone and then hold above it with volume support before treating the trend as repaired.
A close back below the moving-average zone after a breakout, or a break below $23.67, should invalidate the short-term setup.
Mean-reversion setup
If PFE tests the low $23 area without new pipeline, patent, dividend, or guidance damage, compare the selloff with free cash flow, leverage reduction, and normalized EPS guidance.
Do not rely on dividend yield alone. A high yield can reflect market concern about growth, balance sheet repair, or dividend coverage.
Fundamental monitor
Track Q2 and full-year 2026 guidance, oncology growth, obesity pivotal studies, Eliquis and Ibrance patent exposure, COVID product decline, Seagen integration, cost savings, debt, cash flow, and dividend coverage.
Reduce confidence if growth depends mainly on valuation rerating while product revenue, pipeline milestones, or balance sheet metrics fail to improve.
Investment research summary
Four-master Research Compression
Business essence
Pfizer converts scientific research, clinical evidence, patents, regulatory approvals, manufacturing capability, and global physician and payer access into revenue from medicines and vaccines.
Moat
Pfizer has scale, regulatory know-how, global distribution, patents, and clinical data depth. The moat is real but product-specific, and it narrows when exclusivity expires or better therapies emerge.
Munger risk inversion
The thesis fails if patent losses and COVID declines outpace new launches, obesity assets disappoint, Seagen integration under-earns, debt limits capital allocation, or pricing pressure reduces returns.
Management
Albert Bourla has emphasized oncology, obesity, cost discipline, business development, and eventual balance sheet deleveraging. Execution quality will be judged by pipeline conversion and cash returns, not by portfolio size alone.
Industry trend
Biopharma benefits from aging demographics, oncology innovation, vaccines, obesity treatment, and chronic disease demand, but the industry faces patent cliffs, payer pressure, litigation, and binary clinical outcomes.
Valuation and margin of safety
PFE trades at a low sales multiple and high dividend yield versus many healthcare peers, but the margin of safety depends on whether normalized earnings near management guidance are durable after patent and COVID product pressure.
Source-backed data
PFE Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| PFE price | $24.07 at the July 7, 2026 close | StockAnalysis quote snapshot | July 8, 2026 |
| Market capitalization | $137.95 billion, verified as $24.07 x 5.731 billion shares | financial_rigor.py market cap verification | July 8, 2026 |
| Diluted weighted-average shares | 5.731 billion for Q1 2026 | Pfizer Q1 2026 earnings release | July 8, 2026 |
| FY2025 revenue | $62.579 billion | Pfizer 2025 Form 10-K, StockAnalysis, and Macrotrends | July 8, 2026 |
| FY2025 net income | $7.787 billion | Pfizer 2025 Form 10-K, StockAnalysis, and Macrotrends | July 8, 2026 |
| FY2025 free cash flow | $9.075 billion | StockAnalysis cash flow statement and Pfizer filings | July 8, 2026 |
| Q1 2026 cash and short-term investments | $13.075 billion | Pfizer Q1 2026 release and StockAnalysis balance sheet | July 8, 2026 |
| Q1 2026 total debt | $64.455 billion | StockAnalysis balance sheet | July 8, 2026 |
| Q1 2026 revenue | $14.5 billion, up 5% year over year | Pfizer Q1 2026 earnings release | July 8, 2026 |
| 2026 guidance | $59.5 billion to $62.5 billion revenue and $2.80 to $3.00 adjusted diluted EPS | Pfizer Q1 2026 earnings release | July 8, 2026 |
| Valuation checks | 18.37x TTM GAAP EPS, 14.50x free cash flow per share, 1.53x book value, 2.17x sales, and 7.15% dividend yield | financial_rigor.py valuation verification | July 8, 2026 |
| Technical indicators | 50-day moving average around $24.08 to $25.30, 200-day moving average around $25.25 to $25.90, RSI around 39 to 51 | Investing.com and AltIndex technical snapshots | July 8, 2026 |
Frequently Asked Questions
Compare MRK AI stock analysisRead JNJ AI stock forecastReview LLY AI technical analysisExplore Pineify AI Stock Picker
This PFE AI stock analysis is an informational research tool only. It is not investment advice, a recommendation to buy or sell Pfizer Inc., or a guarantee of future returns. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if fundamentals, valuation, patent timing, clinical data, regulation, capital allocation, or market conditions change.